Raising money in medical devices is rarely easy; in fact, just getting past the front door can sometimes be a challenge. But not for ultrasound company, LipoSonix.
The reason: LipoSonix is working on an energy-based alternative to liposuction, whose concept is easy to understand and its appeal immediate to both physicians and patients. Replacing what is now an often messy, painful procedure, LipoSonix offers a quick, painless procedure that allows patients to get up, walk out of the physician's office, and head back to work. LipoSonix still has challenges ahead of it. Having spent much of its time thus far on safety and mechanism of action issues, the company must now prove not only that the technology can achieve the kind of body-sculpting effect it hopes for, but that the effect is long-lasting. Moreover, adoption issues loom large. LipoSonix will have to convince both physicians and patients that their alternative justifies abandoning what is now a widely-accepted procedure. But if they can, LipoSonix' promise could be huge: a better approach to cosmetic surgery in a world where you can never be too rich or too thin.
By David Cassak
Raising money in medical devices is rarely easy; in fact, just getting past the front door can sometimes be a challenge. But not for Seattle-based therapeutic ultrasound company, LipoSonix Inc....
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.
The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.
The whirlwind back-and-forth on US tariffs and Robert F. Kennedy jr.’s plans to deregulate health care have become all-preoccupying, but the National Academy of Medicine was first to set out President Trump’s health administration priorities.
Mikkel Wandahl Pederson, CEO and chief scientific officer at Commit Biologics, discussed the company’s mission to harness the powerful complement system for the treatment of serious diseases.
Phenomix Science presented new data at Digestive Disease Week 2025 showing its machine learning-assisted genetic risk score can predict nausea and side effects from GLP-1 receptor agonists, aiding personalized obesity treatment.
